Cargando…

Human Embryo Models and Drug Discovery

For obvious reasons, such as, e.g., ethical concerns or sample accessibility, model systems are of highest importance to study the underlying molecular mechanisms of human maladies with the aim to develop innovative and effective therapeutic strategies. Since many years, animal models and highly pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosner, Margit, Reithofer, Manuel, Fink, Dieter, Hengstschläger, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828037/ https://www.ncbi.nlm.nih.gov/pubmed/33440617 http://dx.doi.org/10.3390/ijms22020637

Ejemplares similares

Pluripotent Stem Cell-Derived In Vitro Gametogenesis and Synthetic Embryos—It Is Never Too Early for an Ethical Debate
por: Horer, Stefanie, et al.
Publicado: (2023)

Stem Cell-Induced Cell Motility: A Removable Obstacle on the Way to Safe Therapies?
por: Rosner, Margit, et al.
Publicado: (2022)

Three‐dimensional migration of human amniotic fluid stem cells involves mesenchymal and amoeboid modes and is regulated by mTORC1
por: Rosner, Margit, et al.
Publicado: (2021)

Embryoid research calls for reassessment of legal regulations
por: Hengstschläger, Markus, et al.
Publicado: (2021)

Multipotent fetal stem cells in reproductive biology research
por: Rosner, Margit, et al.
Publicado: (2023)

Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis
por: Rosner, Margit, et al.
Publicado: (2011)

Amniotic Fluid Stem Cells: Future Perspectives
por: Rosner, Margit, et al.
Publicado: (2012)

Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1
por: Rosner, Margit, et al.
Publicado: (2017)

DRUGPATH – a novel bioinformatic approach identifies DNA-damage pathway as a regulator of size maintenance in human ESCs and iPSCs
por: Kovacic, Boris, et al.
Publicado: (2019)

Amniotic fluid stem cells and the cell source repertoire for non-invasive prenatal testing
por: Rosner, Margit, et al.
Publicado: (2021)

Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle
por: Rosner, Margit, et al.
Publicado: (2009)

eIF3 controls cell size independently of S6K1-activity
por: Schipany, Katharina, et al.
Publicado: (2015)

Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production
por: Fruhwürth, Stefanie, et al.
Publicado: (2014)

OA02.08. Chick embryo model an experimental model for drug discovery in ayurveda.
por: Tomar, Ekta, et al.
Publicado: (2013)

Reliable Quantification of Protein Expression and Cellular Localization in Histological Sections
por: Schlederer, Michaela, et al.
Publicado: (2014)

Artificial intelligence as a door opener for a new era of human reproduction
por: Hengstschläger, Markus
Publicado: (2023)

Allergens with Protease Activity from House Dust Mites
por: Reithofer, Manuel, et al.
Publicado: (2017)

Insights into Differentiation of Melanocytes from Human Stem Cells and Their Relevance for Melanoma Treatment
por: Mirea, Madalina A., et al.
Publicado: (2020)

Key drivers of biomedical innovation in cancer drug discovery
por: Huber, Margit A, et al.
Publicado: (2015)

Human coronaviruses and therapeutic drug discovery
por: Song, Lan-Gui, et al.
Publicado: (2021)

Modeling enzyme-ligand binding in drug discovery
por: Konc, Janez, et al.
Publicado: (2015)

Beyond Deterministic Models in Drug Discovery and Development
por: Irurzun-Arana, Itziar, et al.
Publicado: (2020)

In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
por: Beedie, Shaunna L., et al.
Publicado: (2016)

Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery
por: Qian, Lu, et al.
Publicado: (2021)

Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders
por: Benchoua, Alexandra, et al.
Publicado: (2021)

Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery()
por: Kell, Douglas B., et al.
Publicado: (2014)

Antileishmanial Drug Discovery and Development: Time to Reset the Model?
por: Olías-Molero, Ana Isabel, et al.
Publicado: (2021)

Drug discovery and development for neglected diseases: the DNDi model
por: Chatelain, Eric, et al.
Publicado: (2011)

Cell and small animal models for phenotypic drug discovery
por: Szabo, Mihaly, et al.
Publicado: (2017)

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine
por: Tan, Linyun, et al.
Publicado: (2023)

Visceral leishmaniasis: Experimental models for drug discovery
por: Gupta, Suman, et al.
Publicado: (2011)

Human embryo implantation
por: Muter, Joanne, et al.
Publicado: (2023)

Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development
por: Lin, Xiying, et al.
Publicado: (2021)

Chemoinformatics and Drug Discovery
por: Xu, Jun, et al.
Publicado: (2002)

Drug metabolism in drug discovery and development
por: Zhang, Zhoupeng, et al.
Publicado: (2018)

Current Screening Methodologies in Drug Discovery for Selected Human Diseases
por: Lage, Olga Maria, et al.
Publicado: (2018)

Strategies for translating proteomics discoveries into drug discovery for dementia
por: Halder, Aditi, et al.
Publicado: (2023)

Advancing drug discovery using the power of the human genome
por: Heilbron, Karl, et al.
Publicado: (2021)

Patient-Derived Organoids as a Model for Cancer Drug Discovery
por: Rae, Colin, et al.
Publicado: (2021)

Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery
por: Mehta, Pakhuri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g2crufmppgsenapm1aglg2srld